Circulating Copper and Liver Cancer

Trends of Copper Homeostasis in Neoplasms: A Systemic Bibliometric from 2013 to 2023

Copper dysregulation is pivotal in tumorigenesis. This study aimed to elucidate the knowledge framework of copper homeostasis within neoplasms utilizing bibliometric analysis. Publications about copper homeostasis in neoplasms from 2013 to 2023 were retrieved from the Web of Science Core Collection and PubMed databases. The bibliometric analysis was conducted using the RStudio, the CiteSpace software, the VOSviewer software, and a bibliometric analysis platform. A total of 1701 articles were indexed from 73 countries and regions. China has emerged as the leading country with a publication proportion of 32.45%, followed by the USA (10.35%) and India (8.41%). Significant collaborations have been conducted among Chinese academic institutions. The Journal of Inorganic Biochemistry emerged as the most prominent journal. Among the 4841 keywords extracted from 671 journals, concepts of cell death, positron emission tomography, and tumor microenvironment emerged as the most significant hotspots. This bibliometric study reviewed significant academic development and synthesized research trends on copper homeostasis in neoplasms, providing a valuable reference for scholars.

Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials

Iron (Fe) and copper (Cu), essential transition metals, play pivotal roles in various cellular processes critical to cancer biology, including cell proliferation, mitochondrial respiration, distant metastases, and oxidative stress. The emergence of ferroptosis and cuproptosis as distinct forms of non-apoptotic cell death has heightened their significance, particularly in connection with these metal ions. While initially studied separately, recent evidence underscores the interdependence of ferroptosis and cuproptosis. Studies reveal a link between mitochondrial copper accumulation and ferroptosis induction. This interconnected relationship presents a promising strategy, especially for addressing refractory cancers marked by drug tolerance. Harnessing the toxicity of iron and copper in clinical settings becomes crucial. Simultaneous targeting of ferroptosis and cuproptosis, exemplified by the combination of sorafenib and elesclomol-Cu, represents an intriguing approach. Strategies targeting mitochondria further enhance the precision of these approaches, providing hope for improving treatment outcomes of drug-resistant cancers. Moreover, the combination of iron chelators and copper-lowering agents with established therapeutic modalities exhibits a synergy that holds promise for the augmentation of anti-tumor efficacy in various malignancies. This review elaborates on the complex interplay between ferroptosis and cuproptosis, including their underlying mechanisms, and explores their potential as druggable targets in both cancer research and clinical settings.